Emalex Biosciences

16 items

April 29, 2026

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first‑in‑class selective dopamine D1 receptor [...]
March 6, 2026

First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy
Study opens pathway to investigational therapy for [...]
February 12, 2026

Biotech Innovation Update
Last year, Paragon Biosciences and [...]
February 28, 2025

Groundbreaking Achievements and Pivotal Milestones for Paragon and its Portfolio Companies
In 2024, Paragon and its [...]
November 3, 2022

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
– Clinical stage biopharmaceutical company completes upsized, [...]
June 24, 2022

Outstanding First Half for Paragon and its Portfolio Companies
Paragon and its portfolio companies continue to [...]
May 25, 2022

Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital [...]
April 5, 2022

Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and [...]